$22.37 Million in Sales Expected for SI-BONE, Inc. (NASDAQ:SIBN) This Quarter

Equities analysts predict that SI-BONE, Inc. (NASDAQ:SIBNGet Rating) will report sales of $22.37 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for SI-BONE’s earnings. The lowest sales estimate is $22.34 million and the highest is $22.40 million. SI-BONE reported sales of $20.44 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 9.4%. The company is expected to announce its next quarterly earnings report after the market closes on Monday, January 1st.

On average, analysts expect that SI-BONE will report full-year sales of $107.69 million for the current year, with estimates ranging from $107.64 million to $107.73 million. For the next financial year, analysts forecast that the firm will post sales of $131.13 million, with estimates ranging from $130.90 million to $131.36 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for SI-BONE.

SI-BONE (NASDAQ:SIBNGet Rating) last announced its quarterly earnings data on Monday, February 28th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.06). The business had revenue of $25.23 million during the quarter. SI-BONE had a negative return on equity of 38.10% and a negative net margin of 62.75%. During the same period in the prior year, the company posted ($0.28) earnings per share.

Several brokerages have weighed in on SIBN. Morgan Stanley dropped their target price on SI-BONE from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 1st. Bank of America dropped their target price on SI-BONE from $43.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday, January 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 target price on shares of SI-BONE in a research report on Monday, January 10th. Zacks Investment Research raised SI-BONE from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Cantor Fitzgerald assumed coverage on SI-BONE in a report on Thursday, April 7th. They set an “overweight” rating and a $34.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $33.44.

Shares of SIBN stock opened at $22.12 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.41 and a quick ratio of 9.73. SI-BONE has a fifty-two week low of $17.96 and a fifty-two week high of $37.21. The stock’s 50-day moving average is $20.88 and its two-hundred day moving average is $21.15. The firm has a market cap of $740.80 million, a P/E ratio of -13.01 and a beta of 1.41.

In other SI-BONE news, Director Jeffrey W. Dunn sold 1,474 shares of the firm’s stock in a transaction that occurred on Monday, April 18th. The stock was sold at an average price of $19.92, for a total value of $29,362.08. Following the sale, the director now owns 152,285 shares of the company’s stock, valued at approximately $3,033,517.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Pisetsky sold 1,994 shares of the firm’s stock in a transaction that occurred on Wednesday, February 16th. The shares were sold at an average price of $20.38, for a total value of $40,637.72. The disclosure for this sale can be found here. Insiders sold a total of 16,946 shares of company stock worth $344,255 in the last ninety days. Insiders own 7.00% of the company’s stock.

Several hedge funds have recently made changes to their positions in SIBN. Morgan Stanley lifted its position in shares of SI-BONE by 38.2% in the 2nd quarter. Morgan Stanley now owns 615,162 shares of the company’s stock worth $19,358,000 after acquiring an additional 170,153 shares during the period. SG Americas Securities LLC lifted its position in shares of SI-BONE by 120.8% in the 3rd quarter. SG Americas Securities LLC now owns 57,205 shares of the company’s stock worth $1,225,000 after acquiring an additional 31,298 shares during the period. New York State Common Retirement Fund lifted its position in shares of SI-BONE by 15.7% in the 3rd quarter. New York State Common Retirement Fund now owns 272,243 shares of the company’s stock worth $5,831,000 after acquiring an additional 36,972 shares during the period. Deutsche Bank AG lifted its position in shares of SI-BONE by 22.2% in the 3rd quarter. Deutsche Bank AG now owns 25,297 shares of the company’s stock worth $542,000 after acquiring an additional 4,604 shares during the period. Finally, Swiss National Bank lifted its position in shares of SI-BONE by 1.6% during the 3rd quarter. Swiss National Bank now owns 58,000 shares of the company’s stock worth $1,242,000 after buying an additional 900 shares during the period.

SI-BONE Company Profile (Get Rating)

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures.

Further Reading

Get a free copy of the Zacks research report on SI-BONE (SIBN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.